The Top 3 Preclinical Considerations in the Discovery and Development of Novel Oncology TherapeuticsHosted By : Andrea Charles
November 6, 2012
predictive toxicology | preclinical considerations | computational biology | clinical drug development | novel oncology therapeutics | Ken Olivier | Merrimack Pharmaceuticals
About this Podcast...
In this interview Kenneth J. Olivier Jr., PhD, Director of Toxicology at Merrimack Pharmaceuticals, speaks to Andrea Charles from Pharma IQ, about what trends he is witnessing in the improvement of safety assessments, his top 3 preclinical considerations in the discovery and development of novel oncology therapeutics and the implications and future considerations for use of computational biology in clinical drug development.
Have Your Say
Rate this feature and give us your feedback in the comments section below
to get access to this White Paper
comments powered by Disqus
Is your R&D Business Ready to Collaborate with External Partners?
October 27, 2015
Pharmaceutical Serialisation and Traceability
Starling Hotel and Conference Centre, Geneva, Switzerland
November 2- 4, 2015
Pharmaceutical Traceability Forum November
November 16- 18, 2015